PMC:7195088 / 22875-25323 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"680","span":{"begin":142,"end":150},"obj":"Species"},{"id":"681","span":{"begin":193,"end":201},"obj":"Species"},{"id":"682","span":{"begin":275,"end":283},"obj":"Species"},{"id":"813","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"814","span":{"begin":164,"end":175},"obj":"Chemical"},{"id":"815","span":{"begin":212,"end":222},"obj":"Chemical"},{"id":"816","span":{"begin":294,"end":305},"obj":"Chemical"},{"id":"947","span":{"begin":133,"end":141},"obj":"Disease"},{"id":"948","span":{"begin":184,"end":192},"obj":"Disease"}],"attributes":[{"id":"A680","pred":"tao:has_database_id","subj":"680","obj":"Tax:9606"},{"id":"A681","pred":"tao:has_database_id","subj":"681","obj":"Tax:9606"},{"id":"A682","pred":"tao:has_database_id","subj":"682","obj":"Tax:9606"},{"id":"A813","pred":"tao:has_database_id","subj":"813","obj":"MESH:C462182"},{"id":"A814","pred":"tao:has_database_id","subj":"814","obj":"MESH:C462182"},{"id":"A815","pred":"tao:has_database_id","subj":"815","obj":"MESH:C086979"},{"id":"A816","pred":"tao:has_database_id","subj":"816","obj":"MESH:C462182"},{"id":"A947","pred":"tao:has_database_id","subj":"947","obj":"MESH:C000657245"},{"id":"A948","pred":"tao:has_database_id","subj":"948","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days).\n• Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04319900, recruiting). Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days).\n• Comparison of favipiravir vs. standard of care in patients with COVID-19. Open-label RCT (NCT04333589, not yet recruiting). Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T20","span":{"begin":27,"end":30},"obj":"Body_part"},{"id":"T21","span":{"begin":41,"end":44},"obj":"Body_part"},{"id":"T22","span":{"begin":1652,"end":1658},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma312401"}],"text":"Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days).\n• Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04319900, recruiting). Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days).\n• Comparison of favipiravir vs. standard of care in patients with COVID-19. Open-label RCT (NCT04333589, not yet recruiting). Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T19","span":{"begin":1652,"end":1658},"obj":"Body_part"}],"attributes":[{"id":"A19","pred":"uberon_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/UBERON_0007311"}],"text":"Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days).\n• Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04319900, recruiting). Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days).\n• Comparison of favipiravir vs. standard of care in patients with COVID-19. Open-label RCT (NCT04333589, not yet recruiting). Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T111","span":{"begin":17,"end":26},"obj":"Disease"},{"id":"T112","span":{"begin":133,"end":141},"obj":"Disease"},{"id":"T113","span":{"begin":184,"end":192},"obj":"Disease"},{"id":"T114","span":{"begin":473,"end":481},"obj":"Disease"},{"id":"T115","span":{"begin":687,"end":695},"obj":"Disease"},{"id":"T116","span":{"begin":974,"end":982},"obj":"Disease"},{"id":"T117","span":{"begin":1052,"end":1060},"obj":"Disease"},{"id":"T118","span":{"begin":1201,"end":1209},"obj":"Disease"},{"id":"T119","span":{"begin":1461,"end":1469},"obj":"Disease"},{"id":"T120","span":{"begin":1753,"end":1761},"obj":"Disease"},{"id":"T121","span":{"begin":2034,"end":2042},"obj":"Disease"},{"id":"T122","span":{"begin":2321,"end":2329},"obj":"Disease"},{"id":"T123","span":{"begin":2399,"end":2407},"obj":"Disease"}],"attributes":[{"id":"A111","pred":"mondo_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A114","pred":"mondo_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A115","pred":"mondo_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A116","pred":"mondo_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A117","pred":"mondo_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A118","pred":"mondo_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A119","pred":"mondo_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A120","pred":"mondo_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A121","pred":"mondo_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A122","pred":"mondo_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A123","pred":"mondo_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days).\n• Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04319900, recruiting). Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days).\n• Comparison of favipiravir vs. standard of care in patients with COVID-19. Open-label RCT (NCT04333589, not yet recruiting). Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T112","span":{"begin":71,"end":72},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T113","span":{"begin":97,"end":98},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T114","span":{"begin":360,"end":364},"obj":"http://purl.obolibrary.org/obo/CLO_0008416"},{"id":"T115","span":{"begin":360,"end":364},"obj":"http://purl.obolibrary.org/obo/CLO_0050081"},{"id":"T116","span":{"begin":488,"end":493},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T117","span":{"begin":989,"end":994},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T118","span":{"begin":1216,"end":1221},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T119","span":{"begin":1318,"end":1319},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T120","span":{"begin":1535,"end":1536},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T121","span":{"begin":1627,"end":1628},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T122","span":{"begin":1768,"end":1773},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T123","span":{"begin":1850,"end":1854},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T124","span":{"begin":2336,"end":2341},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days).\n• Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04319900, recruiting). Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days).\n• Comparison of favipiravir vs. standard of care in patients with COVID-19. Open-label RCT (NCT04333589, not yet recruiting). Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T270","span":{"begin":41,"end":65},"obj":"Chemical"},{"id":"T271","span":{"begin":56,"end":65},"obj":"Chemical"},{"id":"T272","span":{"begin":164,"end":175},"obj":"Chemical"},{"id":"T273","span":{"begin":212,"end":222},"obj":"Chemical"},{"id":"T274","span":{"begin":294,"end":305},"obj":"Chemical"},{"id":"T275","span":{"begin":395,"end":406},"obj":"Chemical"},{"id":"T276","span":{"begin":411,"end":422},"obj":"Chemical"},{"id":"T277","span":{"begin":427,"end":438},"obj":"Chemical"},{"id":"T278","span":{"begin":444,"end":455},"obj":"Chemical"},{"id":"T279","span":{"begin":488,"end":493},"obj":"Chemical"},{"id":"T280","span":{"begin":595,"end":606},"obj":"Chemical"},{"id":"T281","span":{"begin":612,"end":623},"obj":"Chemical"},{"id":"T282","span":{"begin":628,"end":639},"obj":"Chemical"},{"id":"T283","span":{"begin":645,"end":664},"obj":"Chemical"},{"id":"T284","span":{"begin":645,"end":654},"obj":"Chemical"},{"id":"T285","span":{"begin":655,"end":664},"obj":"Chemical"},{"id":"T286","span":{"begin":703,"end":722},"obj":"Chemical"},{"id":"T287","span":{"begin":703,"end":712},"obj":"Chemical"},{"id":"T288","span":{"begin":713,"end":722},"obj":"Chemical"},{"id":"T289","span":{"begin":728,"end":739},"obj":"Chemical"},{"id":"T290","span":{"begin":744,"end":753},"obj":"Chemical"},{"id":"T291","span":{"begin":754,"end":763},"obj":"Chemical"},{"id":"T292","span":{"begin":769,"end":780},"obj":"Chemical"},{"id":"T293","span":{"begin":785,"end":796},"obj":"Chemical"},{"id":"T294","span":{"begin":802,"end":821},"obj":"Chemical"},{"id":"T295","span":{"begin":802,"end":811},"obj":"Chemical"},{"id":"T296","span":{"begin":812,"end":821},"obj":"Chemical"},{"id":"T297","span":{"begin":826,"end":835},"obj":"Chemical"},{"id":"T298","span":{"begin":836,"end":845},"obj":"Chemical"},{"id":"T299","span":{"begin":851,"end":862},"obj":"Chemical"},{"id":"T300","span":{"begin":868,"end":879},"obj":"Chemical"},{"id":"T301","span":{"begin":884,"end":893},"obj":"Chemical"},{"id":"T302","span":{"begin":894,"end":903},"obj":"Chemical"},{"id":"T303","span":{"begin":909,"end":920},"obj":"Chemical"},{"id":"T304","span":{"begin":926,"end":937},"obj":"Chemical"},{"id":"T305","span":{"begin":989,"end":994},"obj":"Chemical"},{"id":"T306","span":{"begin":1118,"end":1136},"obj":"Chemical"},{"id":"T307","span":{"begin":1142,"end":1151},"obj":"Chemical"},{"id":"T308","span":{"begin":1152,"end":1162},"obj":"Chemical"},{"id":"T309","span":{"begin":1216,"end":1221},"obj":"Chemical"},{"id":"T310","span":{"begin":1387,"end":1398},"obj":"Chemical"},{"id":"T311","span":{"begin":1404,"end":1415},"obj":"Chemical"},{"id":"T312","span":{"begin":1420,"end":1431},"obj":"Chemical"},{"id":"T313","span":{"begin":1703,"end":1714},"obj":"Chemical"},{"id":"T314","span":{"begin":1768,"end":1773},"obj":"Chemical"},{"id":"T315","span":{"begin":1837,"end":1849},"obj":"Chemical"},{"id":"T316","span":{"begin":1845,"end":1849},"obj":"Chemical"},{"id":"T317","span":{"begin":1942,"end":1953},"obj":"Chemical"},{"id":"T318","span":{"begin":1959,"end":1970},"obj":"Chemical"},{"id":"T319","span":{"begin":1975,"end":1986},"obj":"Chemical"},{"id":"T320","span":{"begin":1992,"end":2011},"obj":"Chemical"},{"id":"T321","span":{"begin":1992,"end":2001},"obj":"Chemical"},{"id":"T322","span":{"begin":2002,"end":2011},"obj":"Chemical"},{"id":"T323","span":{"begin":2050,"end":2069},"obj":"Chemical"},{"id":"T324","span":{"begin":2050,"end":2059},"obj":"Chemical"},{"id":"T325","span":{"begin":2060,"end":2069},"obj":"Chemical"},{"id":"T326","span":{"begin":2075,"end":2086},"obj":"Chemical"},{"id":"T327","span":{"begin":2091,"end":2100},"obj":"Chemical"},{"id":"T328","span":{"begin":2101,"end":2110},"obj":"Chemical"},{"id":"T329","span":{"begin":2116,"end":2127},"obj":"Chemical"},{"id":"T330","span":{"begin":2132,"end":2143},"obj":"Chemical"},{"id":"T331","span":{"begin":2149,"end":2168},"obj":"Chemical"},{"id":"T332","span":{"begin":2149,"end":2158},"obj":"Chemical"},{"id":"T333","span":{"begin":2159,"end":2168},"obj":"Chemical"},{"id":"T334","span":{"begin":2173,"end":2182},"obj":"Chemical"},{"id":"T335","span":{"begin":2183,"end":2192},"obj":"Chemical"},{"id":"T336","span":{"begin":2198,"end":2209},"obj":"Chemical"},{"id":"T337","span":{"begin":2215,"end":2226},"obj":"Chemical"},{"id":"T338","span":{"begin":2231,"end":2240},"obj":"Chemical"},{"id":"T339","span":{"begin":2241,"end":2250},"obj":"Chemical"},{"id":"T340","span":{"begin":2256,"end":2267},"obj":"Chemical"},{"id":"T341","span":{"begin":2273,"end":2284},"obj":"Chemical"},{"id":"T342","span":{"begin":2336,"end":2341},"obj":"Chemical"}],"attributes":[{"id":"A270","pred":"chebi_id","subj":"T270","obj":"http://purl.obolibrary.org/obo/CHEBI_37416"},{"id":"A271","pred":"chebi_id","subj":"T271","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A272","pred":"chebi_id","subj":"T272","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A273","pred":"chebi_id","subj":"T273","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A274","pred":"chebi_id","subj":"T274","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A275","pred":"chebi_id","subj":"T275","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A276","pred":"chebi_id","subj":"T276","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A277","pred":"chebi_id","subj":"T277","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A278","pred":"chebi_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A279","pred":"chebi_id","subj":"T279","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A280","pred":"chebi_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A281","pred":"chebi_id","subj":"T281","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A282","pred":"chebi_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A283","pred":"chebi_id","subj":"T283","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A284","pred":"chebi_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A285","pred":"chebi_id","subj":"T285","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A286","pred":"chebi_id","subj":"T286","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A287","pred":"chebi_id","subj":"T287","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A288","pred":"chebi_id","subj":"T288","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A289","pred":"chebi_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A290","pred":"chebi_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A291","pred":"chebi_id","subj":"T291","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A292","pred":"chebi_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A293","pred":"chebi_id","subj":"T293","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A294","pred":"chebi_id","subj":"T294","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A295","pred":"chebi_id","subj":"T295","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A296","pred":"chebi_id","subj":"T296","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A297","pred":"chebi_id","subj":"T297","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A298","pred":"chebi_id","subj":"T298","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A299","pred":"chebi_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A300","pred":"chebi_id","subj":"T300","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A301","pred":"chebi_id","subj":"T301","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A302","pred":"chebi_id","subj":"T302","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A303","pred":"chebi_id","subj":"T303","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A304","pred":"chebi_id","subj":"T304","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A305","pred":"chebi_id","subj":"T305","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A306","pred":"chebi_id","subj":"T306","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A307","pred":"chebi_id","subj":"T307","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A308","pred":"chebi_id","subj":"T308","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A309","pred":"chebi_id","subj":"T309","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A310","pred":"chebi_id","subj":"T310","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A311","pred":"chebi_id","subj":"T311","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A312","pred":"chebi_id","subj":"T312","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A313","pred":"chebi_id","subj":"T313","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A314","pred":"chebi_id","subj":"T314","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A315","pred":"chebi_id","subj":"T315","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A316","pred":"chebi_id","subj":"T316","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A317","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A318","pred":"chebi_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A319","pred":"chebi_id","subj":"T319","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A320","pred":"chebi_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A321","pred":"chebi_id","subj":"T321","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A322","pred":"chebi_id","subj":"T322","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A323","pred":"chebi_id","subj":"T323","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A324","pred":"chebi_id","subj":"T324","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A325","pred":"chebi_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A326","pred":"chebi_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A327","pred":"chebi_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A328","pred":"chebi_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A329","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A330","pred":"chebi_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A331","pred":"chebi_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A332","pred":"chebi_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A333","pred":"chebi_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A334","pred":"chebi_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A335","pred":"chebi_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A336","pred":"chebi_id","subj":"T336","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A337","pred":"chebi_id","subj":"T337","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A338","pred":"chebi_id","subj":"T338","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A339","pred":"chebi_id","subj":"T339","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A340","pred":"chebi_id","subj":"T340","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A341","pred":"chebi_id","subj":"T341","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A342","pred":"chebi_id","subj":"T342","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days).\n• Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04319900, recruiting). Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days).\n• Comparison of favipiravir vs. standard of care in patients with COVID-19. Open-label RCT (NCT04333589, not yet recruiting). Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T170","span":{"begin":0,"end":306},"obj":"Sentence"},{"id":"T171","span":{"begin":307,"end":482},"obj":"Sentence"},{"id":"T172","span":{"begin":483,"end":524},"obj":"Sentence"},{"id":"T173","span":{"begin":525,"end":578},"obj":"Sentence"},{"id":"T174","span":{"begin":579,"end":983},"obj":"Sentence"},{"id":"T175","span":{"begin":984,"end":1033},"obj":"Sentence"},{"id":"T176","span":{"begin":1034,"end":1101},"obj":"Sentence"},{"id":"T177","span":{"begin":1102,"end":1210},"obj":"Sentence"},{"id":"T178","span":{"begin":1211,"end":1252},"obj":"Sentence"},{"id":"T179","span":{"begin":1253,"end":1370},"obj":"Sentence"},{"id":"T180","span":{"begin":1371,"end":1470},"obj":"Sentence"},{"id":"T181","span":{"begin":1471,"end":1514},"obj":"Sentence"},{"id":"T182","span":{"begin":1515,"end":1686},"obj":"Sentence"},{"id":"T183","span":{"begin":1687,"end":1762},"obj":"Sentence"},{"id":"T184","span":{"begin":1763,"end":1812},"obj":"Sentence"},{"id":"T185","span":{"begin":1813,"end":1925},"obj":"Sentence"},{"id":"T186","span":{"begin":1926,"end":2330},"obj":"Sentence"},{"id":"T187","span":{"begin":2331,"end":2380},"obj":"Sentence"},{"id":"T188","span":{"begin":2381,"end":2448},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days).\n• Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19. Double-blind RCT (NCT04319900, recruiting). Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days).\n• Comparison of favipiravir vs. standard of care in patients with COVID-19. Open-label RCT (NCT04333589, not yet recruiting). Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}